Humacyte, Inc. (Nasdaq: HUMA) announced the publication of one-year results from its V007 Phase 3 clinical trial in The Lancet ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE